Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

724
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
724
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
Drug Therapy01:28

Drug Therapy

219
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
219
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

412
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
412
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

497
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
497

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Working with a youth mental health apprenticeship scheme to coproduce evidence synthesis: The youth mental health evidence synthesis hub.

JCPP advances·2026
Same author

Reliable Change of Blood-Based Biomarkers Following Acute Sport-Related Concussion: A CARE Consortium Study.

Sports medicine (Auckland, N.Z.)·2026
Same author

Sociodemographic inequalities in non-small cell lung cancer (NSCLC) novel treatments: a national population-based cohort study.

Journal of epidemiology and community health·2026
Same author

'We're the Eyes and Ears… out There': A Qualitative Exploration of the Perceptions and Experiences of Polypharmacy Amongst Home Care Providers.

Health expectations : an international journal of public participation in health care and health policy·2026
Same author

Causes of medication errors in community pharmacies: A meta-ethnography and systematic review.

PloS one·2026
Same author

Guidance for protocol content and reporting of dog-assisted interventions in randomised controlled trials: explanation and elaboration of the SPIRIT 2025 and CONSORT 2025 extensions.

BMC medical research methodology·2026

Related Experiment Video

Updated: Jan 1, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K

Pharmacy-based management for depression in adults.

Jennifer Valeska Elli Brown1,2, Nick Walton3, Nicholas Meader1,2

  • 1University of York, Cochrane Common Mental Disorders, York, UK.

The Cochrane Database of Systematic Reviews
|December 24, 2019
PubMed
Summary

Community pharmacists can improve antidepressant medication adherence. However, pharmacy-based management interventions do not significantly change depression symptoms compared to usual care.

More Related Videos

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

470
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.2K

Related Experiment Videos

Last Updated: Jan 1, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K
Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

470
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.2K

Area of Science:

  • Pharmacology and Pharmacy Practice
  • Mental Health Research
  • Evidence-Based Medicine

Background:

  • High rates of antidepressant non-adherence (around 50% discontinue within six months) necessitate improved management strategies.
  • Community pharmacists, with their accessibility and expertise, are well-positioned to manage antidepressant therapy.
  • The effectiveness and acceptability of pharmacist-led interventions for depression remain under-investigated.

Purpose of the Study:

  • To evaluate the impact of pharmacy-based management interventions on depression outcomes in adults.
  • To compare pharmacy-based interventions against active controls, waiting lists, or treatment as usual.
  • To assess depression symptom change, intervention acceptability, and medication adherence.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials (RCTs) and cluster-RCTs.
  • Searched multiple databases (Cochrane, MEDLINE, Embase, PsycINFO) up to December 2018.
  • Included studies involving adults (16+) with depression, comparing pharmacy interventions to controls, assessing specified outcomes.

Main Results:

  • Meta-analyses showed no significant difference in depression symptom change between pharmacy management and treatment as usual (moderate to high-certainty evidence).
  • Medication adherence was significantly improved with pharmacy-based management (high-certainty evidence).
  • Acceptability showed no significant difference, though evidence was of moderate certainty and inconclusive.

Conclusions:

  • Pharmacy-based management does not appear to improve depression symptom change compared to usual care.
  • While interventions enhance medication adherence, their impact on depression symptom severity requires further investigation.
  • More research is needed to clarify the role and effectiveness of pharmacists in managing depression.